SarahProehlMD

Obstetrics & Gynecology • Brisbane, CA

Director, Clinical Development - Myovant Sciences

Join to view full profile

Dr. Proehl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Proehl's full profile

Already have an account?

Office
2000 Sierra Point Pkwy
Fl 9
Brisbane, CA 94005
Phone+1 650-502-6928

Education & Training

University of California (San Diego) Medical CenterResidency, Obstetrics and Gynecology, 2013 - 2017
Washington University in St. Louis School of MedicineClass of 2013
Massachusetts Institute of TechnologyBS, Chemistry, 2005 - 2009

Certifications & Licensure

CA State Medical License 2014 - 2026
MT State Medical License 2020 - 2026
CO State Medical License 2018 - 2025
WY State Medical License 2020 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology

Publications & Presentations

PubMed

18 citations
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial
Tessa Madden, Sarah Proehl, Jenifer E. Allsworth, Gina M. Secura, Jeffrey F. Peipert
American Journal of Obstetrics and Gynecology. 2012-02-01
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Elizabeth A Stewart, Ayman Al-Hendy, Andrea S Lukes, O Sandra Madueke-Laveaux, Emily Zhu
American Journal of Obstetrics and Gynecology. 2024-02-01